DOD taps Val­isure to car­ry out drug qual­i­ty re­views amid gener­ic short­ages, con­cerns

The De­part­ment of De­fense has se­lect­ed the drug qual­i­ty test­ing com­pa­ny Val­isure to car­ry out qual­i­ty rat­ings for drugs sup­plied to the de­part­ment as law­mak­ers and the FDA are fo­cused on rem­e­dy­ing qual­i­ty con­cerns and re­cent short­ages.

The Val­isure con­tract ful­fills a re­quire­ment of the FY2023 Na­tion­al De­fense Au­tho­riza­tion Act, which di­rect­ed DOD to “as­sess risks to the De­part­ment’s phar­ma­ceu­ti­cal sup­ply chain.” The project aims to re­ward qual­i­ty man­u­fac­tur­ers and pre­vent in­ad­e­quate drugs from reach­ing mil­i­tary ser­vice mem­bers and vet­er­ans, Val­isure said in a press re­lease Tues­day. The FDA is sim­i­lar­ly at­tempt­ing to in­sti­tute qual­i­ty met­rics to fur­ther in­cen­tivize good ac­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER